Skip to main content

View full-text article in PMC

. 2006 Feb 1;2006(1):59206. doi: 10.1155/MI/2006/59206

Table 1.

Baseline characteristics of the study groups (mean ± SD).


	Group 1	Group 2	Group 3
	Control	Long standing IDDM	Newly diagnosed IDDM
	(C)	(LS-IDDM)	(ND-IDDM)

			Before treatment	After treatment	P-value
			(BT)	(AT)	P-value

n	25	15	12	12

Glucose (mg/dL)	84.8 ± 13.8	158.3 ± 21.7	470.9 ± 98.1a, b	145.5 ± 24.4	aP < .01	ND-IDDM versus C
					aP < .01	ND-IDDM versus
						LS-IDDM
					bP < .01	LS-IDDM versus C
					P < .001	ND-IDDM
						(BT versus AT)

HbA1c (%)	5.3 ± 0.7	8.0 ± 1.2b	9.9 ± 1.4a	8.6 ± 1.1	aP < .01	ND-IDDM versus C
					aP < .01	ND-IDDM versus
						LS-IDDM
					bP < .01	LS-IDDM versus C
					P < .05	ND-IDDM
						(BT versus AT)

Microalbuminuria (mg/L)	6.4 ± 1.0	8.1 ± 1.5	10.2 ± 3.8a	9.4 ± 2.9	aP < .001	ND-IDDM versus C
					aP < .001	ND-IDDM versus
						LS-IDDM

Urea (mg/dL)	21.8 ± 4.2a	30.7 ± 6.6b	38.1 ± 10.6	31.4 ± 11.8	aP < .01	C versus LS-IDDM
					aP < .01	C versus ND-IDDM
					bP < .05	ND-IDDM versus
						LS-IDDM
					P < .05	ND-IDDM
						(BT versus AT)

Creatinine (mg/dL)	0.5 ± 0.1	0.8 ± 0.1	0.9 ± 0.2a	0.8 ± 0.2	aP < .01	ND-IDDM versus C
					aP < .01	ND-IDDM versus
						LS-IDDM

Creatinine clearance (ml/dk)	80.5 ± 10.6a	56.7 ± 10.9	52.4 ± 13.7	50.1 ± 14.1	aP < .01	C versus LS-IDDM
Creatinine clearance (ml/dk)	80.5 ± 10.6a	56.7 ± 10.9	52.4 ± 13.7	50.1 ± 14.1	aP < .01	C versus ND-IDDM

ASO (U/mL)	0.2 ± 0.04a	1.5 ± 0.3	2.0 ± 0.5	1.3 ± 0.4*	aP < .01	C versus LS-IDDM
					aP < .01	C versus ND-IDDM
					P < .05	ND-IDDM
					P < .05	(BT versus AT)

CRP (mg/L)	0.3 ± 0.04	0.9 ± 0.2	1.3 ± 0.4a	0.9 ± 0.3	aP < .05	ND-IDDM versus C
					aP < .05	ND- IDDM versus
						LS-IDDM

WBC (/mm³)	7745 ± 1412	12126 ± 3611a	9294 ± 1647	8548 ± 1593	aP < .05	LS-IDDM versus C
					aP < .05	LS-IDDM versus
						ND-IDDM